Compositions and methods for identification of relapse risk and treatment in patients with colorectal cancer
AssigneeGeorgetown University
InventorsAnton Wellstein, Narayan Shivapurkar
Life of this patent
Estimating the term…
Abstract
In certain aspects, the disclosure relates to methods of predicting recurrence of colorectal cancer by using a combination of microRNAs in the circulation, wherein the microRNAs are selected from the group consisting of miR-15a, miR-103, miR-148a, miR-320a, miR-451 and miR-596. In other aspects, the disclosure relates to methods of treating colorectal cancer by administering a therapeutic agent after determining an increased risk of recurrence.
Claims40
A method for predicting recurrence of early stage colorectal cancer in a patient, comprising:
- a) providing a biological material comprising circulating microRNAs from a patient diagnosed with stage 0, stage I or stage II colorectal cancer,
- b) measuring in the biological material the levels of two or more microRNAs selected from:
- miR-15a, miR-103, miR-148a, miR-320a, miR-451 and miR-596, and
- c) evaluating the measured levels;
- wherein the measured levels are indicative of a risk of recurrence of the cancer.
A method for predicting recurrence of early stage colorectal cancer in a patient, comprising:
- a) providing a biological material comprising circulating microRNAs from a patient diagnosed with stage 0, stage I or stage II colorectal cancer,
- b) requesting a test comprising measuring in the biological material the levels of two or more microRNAs selected from:
- miR-15a, miR-103, miR-148a, miR-320a, miR-451 and miR-596, and
- c) evaluating the measured levels;
- wherein the measured levels are indicative of a risk of recurrence of the cancer.
A method for determining a treatment regimen for a patient diagnosed with early stage colorectal cancer, comprising:
- a) providing a biological material comprising circulating microRNAs from a patient diagnosed with stage 0, stage I or stage II colorectal cancer,
- b) measuring in the biological material the levels of two or more microRNAs selected from:
- miR-15a, miR-103, miR-148a, miR-320a, miR-451 and miR-596,
- c) evaluating the measured levels, and
- d) providing additional cancer therapy, after surgical resection of the colorectal cancer, to the patient if the measured levels are indicative of a high risk of recurrence of the cancer.
A method for determining a treatment regimen for a patient diagnosed with early stage colorectal cancer, comprising:
- a) providing a biological material comprising circulating microRNAs from a patient diagnosed with stage 0, stage I or stage II colorectal cancer,
- b) requesting a test comprising measuring in the biological material the levels of two or more microRNAs selected from:
- miR-15a, miR-103, miR-148a, miR-320a, miR-451 and miR-596,
- c) evaluating the measured levels;
- and
- d) providing additional cancer therapy, after surgical resection of the colorectal cancer, to the patient if the measured levels are indicative of a high risk of recurrence of the cancer.
A method for treating early stage colorectal cancer in a patient in need thereof, comprising:
- a) providing a biological material comprising circulating microRNAs from a patient diagnosed with stage 0, stage I or stage II colorectal cancer,
- b) measuring in the biological material the levels of two or more microRNAs selected from:
- miR-15a, miR-103, miR-148a, miR-320a, miR-451 and miR-596,
- c) evaluating whether the patient is at risk of recurrence of the cancer based on the levels of the microRNAs in the biological material, and
- d) if the measured levels of the microRNAs in the biological material are indicative of a high risk of recurrence, (i) monitor the patient at more frequent intervals or using tests that exceed the standard of care, and/or (ii) provide additional treatment that exceeds the standard of care.
A method for treating early stage colorectal cancer in a patient in need thereof, comprising:
- a) providing a biological material comprising circulating microRNAs from a patient diagnosed with stage 0, stage I or stage II colorectal cancer,
- b) requesting a test comprising measuring in the biological material the levels of two or more microRNAs selected from:
- miR-15a, miR-103, miR-148a, miR-320a, miR-451 and miR-596,
- c) evaluating whether the patient is at risk of recurrence of the cancer based on the levels of the microRNAs in the biological material, and
- d) if the measured levels of the microRNAs in the biological material are indicative of a high risk of recurrence, (i) monitor the patient at more frequent intervals or using tests that exceed the standard of care, and/or (ii) provide additional treatment that exceeds the standard of care.
A kit for measuring the levels of two or more microRNAs selected from:
- miR-15a, miR-103, miR-148a, miR-320a, miR-451 and miR-596, comprising reagents for specifically measuring the levels of the selected microRNAs.
Dependencies are inferred from the claim text.